CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...

sNDA accepted for Priority Review Datopotamab deruxtecan (AstraZeneca and Daiichi Sankyo) TROP2-directed DXd antibody drug conjugate Treatment of adults with locally advanced or metastatic ...